tiprankstipranks
Trending News
More News >

Akeso’s Innovative Cancer Drug Advancing Globally

Akeso’s Innovative Cancer Drug Advancing Globally

Akeso, Inc. (HK:9926) has released an update.

Confident Investing Starts Here:

Akeso, Inc. has announced that its Phase III clinical trial results for ivonescimab, a first-in-class PD-1/VEGF bi-specific immuno-therapy drug for advanced lung cancer, will be presented at the 2024 World Conference on Lung Cancer. The drug, which has shown superior efficacy to pembrolizumab in a head-to-head setting, has also been submitted for supplemental New Drug Application in China. Ivonescimab has already been approved in China for a different indication and is currently undergoing multiple clinical trials for various cancers.

For further insights into HK:9926 stock, check out TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App